Additional file 1 of Lack of concentration-dependent local toxicity of highly concentrated (5%) versus conventional 0.5% bupivacaine following musculoskeletal surgery in a rat model

Autor: Steverink, Jasper G., van Tol, Floris R., Bruins, Suzanne, Smorenburg, Andre J., Tryfonidou, Marianna A., Oosterman, Bas J., van Dijk, Marijke R., Malda, Jos, Verlaan, Jorrit-Jan

Additional file 1.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8c90276e0f213a723edbc801f32b15

Lack of concentration-dependent local toxicity of highly concentrated (5%) versus conventional 0.5% bupivacaine following musculoskeletal surgery in a rat model

Autor: Steverink, Jasper G, van Tol, Floris R, Bruins, Suzanne, Smorenburg, Andre J, Tryfonidou, Marianna A, Oosterman, Bas J, van Dijk, Marijke R, Malda, Jos, Verlaan, Jorrit-Jan, Chirurgie, CS_Locomotion, Equine Musculoskeletal Biology

Publikováno v: Journal of Experimental Orthopaedics, 10(1), 1. Springer Berlin

Purpose Various sustained-release formulations incorporate high bupivacaine concentrations but data on local toxicity is lacking. This study explores local toxic effects of highly concentrated (5%) bupivacaine compared to clinically used concentratio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d781344ffe0f81e8e9b852fee8e1aba
https://doi.org/10.1186/s40634-023-00591-2

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Autor: Bonten MJ; From the Julius Center for Health Sciences and Primary Care (M.J.M.B., S.M.H., M.B., C.H.W., A.M.M.D., T.J.M.V.) and the Department of Medical Microbiology (M.J.M.B., S.M.H., M.B., C.H.W., A.M.M.D., T.J.M.V.), University Medical Center (UMC) Utrecht, and the Department of Immunology and Infectious Diseases, Wilhelmina Children's Hospital, UMC Utrecht (A.M.M.D., E.A.M.S.), Utrecht, Research Center Linnaeus Institute, Spaarne Hospital, Hoofddorp (A.M.M.D.), and Julius Clinical, Zeist (R.L., B.O., N.V., E.C., A.S., D.E.G.) - all in the Netherlands; Pfizer Vaccine Clinical Research, Maidenhead, United Kingdom (C.W., S.G., M.P., A.M., A.M.-H., H.S., T.M., G.C.); Pfizer Vaccine Clinical Research, Collegeville, PA (S.P., E.A.E.); Pfizer Vaccine Research and Early Development (M.W.P., K.U.J.) and Pfizer Vaccine Clinical Research (D.A.S., E.A.E., W.C.G.), Pearl River, NY; and Pfizer Vaccine Clinical Research, Berlin (B.S.-T.)., Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE

Publikováno v: The New England journal of medicine [N Engl J Med] 2015 Mar 19; Vol. 372 (12), pp. 1114-25.